Real-World Burden of Immunosuppressant-Treated Lupus Nephritis: A German Claims Database Analysis.

ABSTRACT:

Introduction

This retrospective cohort study (GSK213737) aimed to characterize treatment patterns, healthcare resource utilization (HCRU), and costs in patients with lupus nephritis (LN) initiating immunosuppressant therapy in clinical practice in Germany, to better understand the full picture of the real-world burden of LN.

Methods

Adult patients with LN who initiated mycophenolate mofetil (MMF), intravenous cyclophosphamide (CYC), azathioprine (AZA), tacrolimus, cyclosporin A, or rituximab therapy in 2011-2017 (index therapy) were identified from the Betriebskrankenkassen German Sickness Fund database. Treatment patterns, including immunosuppressant discontinuations, and therapy switches, were assessed (maximum follow-up 4 years). Corticosteroid use, HCRU, and total econom

SUBMITTER: Garal-Pantaler E 

PROVIDER: S-EPMC10796872 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature